Repligen extends Cytiva supply agreement for ligand manufacture through 2025

REPLIGEN CORP

Long-term supply agreement with Cytiva Sweden AB extended through 2025.
Covers contract manufacture of Cytiva ligands at Repligen's Waltham, MA and Lund, Sweden facilities.
No financial terms or volume commitments disclosed in the filing.

item 8.01

REPLIGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-21-265002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.